Qiming Venture Partners Portfolio Companies Dominate 2025 New Economy Top 500 List
This ranking systematically maps the landscape, growth momentum, and evolutionary trajectory of China's new economy enterprises.
Recently, the China Enterprise Evaluation Association released its New Economy Enterprises TOP 500 list for the sixth consecutive year. The ranking systematically maps the development landscape, growth momentum, and evolution trends of China's new economy enterprises. Qiming Venture Partners portfolio companies Xiaomi (01810.HK), Meituan (03690.HK), Insta360 (688775.SH), MicroPort EP MedTech (688617.SH), Roborock (688169.SH), Gan & Lee Pharmaceuticals (603087.SH), Bilibili (NASDAQ:BILI, 09626.HK), Tigermed (300347.SZ, 03347.HK), SinoCellTech (688520.SH), Meitu (01357.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), and InventisBio (688382.SH) were selected.
Xiaomi, Meituan Insta360, MicroPort EP MedTech Roborock, Gan & Lee Pharmaceuticals Bilibili, Tigermed SinoCellTech, Meitu Zai Lab, CanSino Biologics, InventisBio
Selected for
2025 New Economy Enterprises TOP 500
Selection Criteria
This year's evaluation screened over 15,000 market entities to form a sample pool of more than 5,000 companies, using market valuation as of June 30, 2025 as the primary ranking metric. The methodology incorporates 15 sub-indicators across seven categories: enterprise scale, profitability, growth velocity, innovation-driven performance, social contribution, social impact, and internationalization level. The innovation-driven indicator carries the highest weight at 25%. All data underwent multiple rounds of cross-verification to ensure the results are objective, traceable, and auditable.
The China Enterprise Evaluation Association noted that shifts in enterprise rankings reflect a broader transition in China's new economy competition — moving beyond platform traffic and business model rivalry toward technological industrialization, engineering implementation, and scalable delivery capabilities. Overall, regional development of China's new economy is evolving from scale aggregation to quality improvement, with cities continuously strengthening modern industrial systems, innovation ecosystems, capital element support, and enterprise capability enhancement to jointly promote diversified, coordinated, and high-quality development of new economy industries.
Source | China Enterprise Evaluation Association
Past Coverage
Qiming Weekly | Qiming Venture Partners Portfolio News Vol. 12, April 7, 2026 Qiming Perspectives | Duane Kuang: Over the Next 20 Years, Investing in AI Is China's Greatest Investment Certainty Qiming Honors | Five Qiming Venture Partners Investors Named to 2025 Forbes China Midas List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in the Technology and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative enterprises, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), HopeMed, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, and StepFun.